Loading…
← CockpitCompetitor Analysis › 688656.SS HOB Biotech Group Corp., Ltd. Class AOpen in the cockpit ↗

HOB Biotech Group Corp., Ltd. Class A688656.SSCompetitor analysis, valuation and peers

China · CNY·Health Care›Medical Specialties

Chinese biotechnology company; specific product/therapeutic focus not independently confirmed.

Momentum neutral 56
Mkt cap
$858M
US dollars, full cap
Free float
100%
of shares outstanding
$/day
$7.57M
20-day average traded
Fwd P/E
166.9×
forward earnings
ROIC−WACC
-1.0 pp
WACC 8.7%
Hurdle
+25 pp
Req g minus delivered
Next earnings
162 days
29 Apr 2027
Close · CNYCN¥90.36
1D-2.0%
1W-14.3%
1M-13.8%
3M-2.9%
6M-33.4%
YTD-41.2%
1Y-46.5%
ATR %6.7%
52w lowhigh58.4% off high

What HOB Biotech does

Chinese biotechnology company; specific product/therapeutic focus not independently confirmed.

Where it sits in the supply chain

  • Health Care
  • Biotechnology

Moat: none

Headquarters: China · Employees: 546

HOB Biotech at a glance

Size HOB Biotech (688656.SS) is a China Health Care company (Medical Specialties) with a market value of $858M, the 2461st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥90.36 on 18 Nov 2026.

Performance Over six months the shares fell 33.4%, against -13.6% for the median peer and -20.0% for the China market (cap-weighted) — 6th lowest of 21 in its peer set.

Growth Revenue grew 6.4% over the last twelve months (peer median +10.4%); the operating margin is 7.2% (peer median 10.0%).

Valuation It trades at 166.9× forward earnings against a peer median of 24.1× (2nd most expensive of 15).

Price implies For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 1.0 points below its cost of capital (8.7% WACC).

Next results Next results expected around 29 Apr 2027 (exchange calendar; dates can move).

Relative performance

608010021 May 202621 Aug 202618 Nov 2026Peer median 87688656.SS 67
Six months, rebased to 100: HOB Biotech against the median of its 20 peers (local-currency closes).

HOB Biotech financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥412MCN¥395MCN¥398MCN¥390MCN¥317M
Revenue growth—-1%+2%+23%—
Gross profitCN¥277MCN¥201MCN¥235MCN¥227MCN¥187M
EBITDAn/aCN¥87.4MCN¥98.2MCN¥101MCN¥79.8M
Net incomeCN¥26.2MCN¥23.2MCN¥36.8MCN¥47.3MCN¥41.7M
Free cash flowCN¥66.8M-CN¥961,330-CN¥53.3M-CN¥75.3M-CN¥162M
Capital expenditureCN¥26.7MCN¥73.9MCN¥155MCN¥178MCN¥220M
Total debtCN¥11.5MCN¥47.4MCN¥118MCN¥55.8MCN¥65.4M

Quarterly statements and history in the cockpit →

HOB Biotech competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%-20%-10%0%30160200265868827736006033676886266887671187688575301580KIDSBVS688068AORTMCAPAMS096530SETL688656.SS6-month return →1-month return →
Up and to the right = strong over both horizons. HOB Biotech is the large dot.

Fundamentals: revenue growth against valuation

0%+20%+40%0×200×400×00265836006033676886266887671187688575301580BVSAORTKURNAMS096530688656.SSRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. HOB Biotech is the large dot.

Capital: growth delivered against growth the price implies

0%+20%+40%0%20%40%30160200265836006033671187688575301580BVS688805MCAPAMS096530688656.SSGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. HOB Biotech is the large dot.

HOB Biotech competitors and peer comparison

How HOB Biotech compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

HOB Biotech against its 20 peers (data as of 18 Nov 2026)
Measure688656.SSPeer medianRank in peer set
1-month return-13.8%-6.4%6th lowest of 21
6-month return-33.4%-13.6%6th lowest of 21
Distance from 52-week high-58.4%-41.1%4th lowest of 21
Revenue growth (TTM)+6.4%+10.4%10th lowest of 21
Operating margin7.2%10.0%8th lowest of 21
Forward P/E166.9×24.1×2nd most expensive of 15
Growth the price implies (Req g, 7 yrs)37.6%5.1%most demanding of 13
Growth delivered (Del g)+12.4%+11.7%6th highest of 13
Hurdle (Req g minus delivered)+25.2 pp-4.3 ppmost demanding of 13
ROIC minus cost of capital-1.0 pp+2.0 pp9th lowest of 21

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
HOB Biotech 688656.SSChina$858M-33%+6%7%166.9×37.6%+12.4%
Shantou Institute of Ultrasonic Instruments 301602.SZChina$858M-25%+4%30%n/a11.1%+4.6%
Beijing SDL Technology 002658.SZChina$864M-34%-13%9%22.4×16.8%+2.9%
Tinavi Medical Technologies 688277.SSChina$872M-36%-2%-59%n/an/an/a
Modern Dental 3600.HKHong Kong$844M+24%+12%22%8.5×-7.1%+11.3%
Cisen Pharmaceutical 603367.SSChina$843M-15%-6%8%7.9×-14.6%-1.3%
Xiangyu Medical 688626.SSChina$877M-38%0%4%56.2×n/an/a
Hangzhou Biotest Biotech 688767.SSChina$878M-12%-4%3%37.0×n/an/a
Cofoe Medical Technology 1187.HKHong Kong$836M-11%+40%10%13.1×-6.4%+6.6%
Shenzhen YHLO Biotech 688575.SSChina$882M-16%+3%12%30.7×2.0%+12.7%
Aidite (Qinhuangdao) Technology 301580.SZChina$888M-12%+17%18%26.2×19.3%+23.3%
OrthoPediatrics KIDSUnited States$826M+71%+16%-8%n/an/an/a
Bioventus BVSUnited States$895M-3%+4%10%13.0×7.5%+12.1%
Ningbo Jansen Superconducting Technologies 688805.SSChina$818M-36%+36%16%n/a35.6%+17.1%
Beijing Hotgen Biotech 688068.SSChina$815M-37%+8%-94%n/an/an/a
Artivion AORTUnited States$905M-18%+14%5%383.6×n/an/a
Kuros Biosciences KURN.SWSwitzerland$907M-12%+41%6%70.5×n/an/a
MedCap MCAP.STSweden$811M-4%+17%15%25.8×2.7%+20.9%
Advanced Medical Solutions AMS.LUnited Kingdom$811M+27%+6%12%20.7×20.0%+21.4%
Seegene 096530.KSSouth Korea$808M-26%+13%13%20.0×-6.7%-15.9%
Standard Engineering Technology SETL.NSIndia$783M+168%+45%14%n/an/an/a

Questions

Which companies are HOB Biotech's closest peers?
The cockpit's peer set: Shantou Institute of Ultrasonic Instruments (301602.SZ), Beijing SDL Technology (002658.SZ), Tinavi Medical Technologies (688277.SS), Modern Dental (3600.HK), Cisen Pharmaceutical (603367.SS), Xiangyu Medical (688626.SS), Hangzhou Biotest Biotech (688767.SS), Cofoe Medical Technology (1187.HK).
Is HOB Biotech expensive compared with its peers?
On forward p/e it trades at 166.9× against a peer median of 24.1×, 2nd most expensive of 15 in its peer set. For today's price to make sense, revenue must grow about 38% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is +25 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has HOB Biotech stock performed?
Over six months to 18 Nov 2026 the shares returned -33.4% against -13.6% for the median peer; over one year -46.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.